Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05858918
Other study ID # IR.SUMS.MED.REC.1401.351
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 1, 2022
Est. completion date March 1, 2023

Study information

Verified date May 2023
Source Shiraz University of Medical Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Elective PCI were included in the study. Patients were randomized into two different groups. One group took ASA 80 mg once daily and clopidogrel 75 mg once a day, and the other one took ASA 80 mg once a day and ticagrelor 90 mg twice a day. After six months of close follow-up, patients were asked to give a score to their dyspnea and asked about the major advance cardiovascular events ( MACE)


Description:

Clinical data of this Randomized Clinical Trial (RCT) study was gathered from patients referred to Prof. Kojuri cardiovascular clinic (Shiraz, Iran, Email: kojurij@yahoo.com , webpage: http://kojuriclinic.com/ ) from October 2022 to March 2023. The inclusion criterion was experiencing elective percutaneous coronary intervention (PCI). Patients diagnosed with hypersensitivity to either ticagrelor or clopidogrel or the ones having any other contraindications such as active pathological bleeding, were excluded from the study. Patients who consumed anticoagulants in the course of their medical therapy were also excluded. Basic clinical information of all patients such as diabetes mellitus (diagnosed based on ADA 2018 criteria [23]), hypertension (defined as systolic blood pressure > 130 mmHg or diastolic blood > 80 mmHg based on 2017 ACC/AHA hypertension guideline [24]), dyslipidemia, anemia (defined according to 1968 Who definition [25]), asthma (diagnosed based on 2007 NAEPP criteria [26]) , chronic obstructive pulmonary disease (diagnosed according to 2020 GOLD criteria [27]), and atrial fibrillation (AF) were recorded. Furthermore, other clinical data such as body mass index (normal; 18.5 to 24.9, overweight; 25 to 29.9 and obesity; higher than 30), left ventricle ejection fracture (LVEF), and heart failure (classified based on 2001 ACC/AHA heart failure classification [28]), history of using tobacco within the past 3 months, and past drug history were also recorded. Major bleeding was defined according to the Thrombolysis in Myocardial Infarction (TIMI) criteria: intracranial bleeding, hemorrhage with a hemoglobin decrease of at least 5 g/dL, or fatal bleeding that caused death within 7 days [29]. Patients were asked to give a score to their dyspnea based on the 10 point Likert scale before undergoing PCI. Score 1-3 were considered mild, score 4-7 were considered moderate, and score 7-10 were considered severe. Patients were randomized using the Block randomization method with block size=4 into two different groups. One group took acetylsalicylic acid (ASA) 80 mg once daily and clopidogrel 75 mg that is produced by Sanofi company available in market as Plavix once a day, and the other one took ASA 80 mg once a day and ticagrelor 90 mg that is produced by Abidi company available in market as Brilavus twice a day. The patients were completely informed about the advantages and disadvantages of the study, and inform consents were taken from participants. Patients who desired not to participate were excluded from the study. Participants were told to take their medications regularly, and they were also encouraged to call us immediately if they faced any medical problem for further investigation. After six months of close follow-up, patients were asked to give a score to their dyspnea happened after PCI, based on the 10 point Likert scale. They were also asked about having dyspnea on exertion, paroxysmal nocturnal dyspnea (PND), any bleeding such as GI bleeding, and occurrence of major adverse cardiovascular event (MACE; defined as acute coronary syndrome (ACS), stroke, revascularization, hospitalization due to heart failure, and cardiac death.) [29] We followed the patients by using their phone numbers which were obtained at the beginning of the study. For statistical analyses we used IBM SPSS software version 25. Independent-sample t tests and one-way ANOVA were used for parametric variables. The Mann-Whitney U test and Kruskal-Wallis test were used for nonparametric data. Values of p <0.05 were considered significant. The study protocol was based on Helsinky declaration, all patients were filled the written consent, The study protocol was approved by Ethical committee of Shiraz University of medical sciences under the number of IR.SUMS.MED.REC.1401.351.


Recruitment information / eligibility

Status Completed
Enrollment 476
Est. completion date March 1, 2023
Est. primary completion date March 1, 2023
Accepts healthy volunteers No
Gender All
Age group 50 Years to 76 Years
Eligibility Inclusion Criteria: - Experiencing elective percutaneous coronary intervention (PCI). Exclusion Criteria: - Patients diagnosed with hypersensitivity to either ticagrelor or clopidogrel - Active pathological bleeding - Patients who consumed anticoagulants in the course of their medical therapy

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Clopidogrel
Treatment with dual antiplatelet drug,aspirin 80 mg PO daily with clopidogrel 75 mg PO daily
Ticagrelor
Treatment with dual antiplatelet drug,aspirin 80 mg PO daily with ticagrelor 90 mg PO twice daily

Locations

Country Name City State
Iran, Islamic Republic of Professor Kojuri Cardiology Clinic Shiraz

Sponsors (1)

Lead Sponsor Collaborator
Shiraz University of Medical Sciences

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary dyspnoea feeling discomfort with respiration, based on 10 grade Likert grade ( minimum 0 and maximum 10, higher worse) 6 months
Primary Number of patients with major adverse cardiovascular events post angioplasty and stenting patients who developed major events, acute coronary syndrome (ACS), stroke, revascularization, hospitalization due to heart failure, and cardiac death 6 months
Secondary Number of patients with bleeding post angioplasty patients who developed minor or major bleeding 6 months
Secondary PND Number of patients post angioplasty who developed paroxysmal nocturnal dyspnoea ( (waking from sleep with sudden dyspnoea) 6 months
See also
  Status Clinical Trial Phase
Completed NCT04795505 - Effect of Tertiary A-level Hospital Remote Intervention on MACCE, Adherence to Drugs and Risk Factors Control in Patients With Stable Coronary Artery Disease Compared With Traditional Community Hospital Follow-up
Recruiting NCT04144881 - Angiographic Control vs. Ischemia-driven Management of Patients Treated With PCI on Left Main With Drug-eluting Stents N/A
Completed NCT03539627 - Azilsartan Medoxomil in Hypertensive pAtients With Stable Ischemic Heart Disease and DiabEtes MEllitus.
Recruiting NCT06075602 - COMPLEX Registry - A Prospective COhort Study to Describe the Management and Outcomes of Patients Presenting With compLEX and Calcified Coronary Artery Disease
Terminated NCT02440646 - Natural History of Coronary Atherosclerosis in Real-World Stable Chest Pain Patients Underwent Computed Tomography Angiography in Comparison With Invasive Multimodality Imaging
Completed NCT03718559 - Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease Phase 4
Recruiting NCT03075124 - Effect of External Counter Pulsation on Coronary Artery Disease Phase 3
Recruiting NCT04988685 - SIROOP Registry - A Prospective Registry Study to Evaluate the Outcomes of Coronary Artery Disease Patients Treated With SIROlimus Or Paclitaxel Eluting Balloon Catheters
Recruiting NCT03911895 - Impact of Stent Length on Short Term Outcomes in Patients With Stable Coronary Disease Undergoing PCI
Enrolling by invitation NCT04810364 - HIV Infection And Evolvement of Atherosclerotic Plaque
Withdrawn NCT04795492 - Effect of Remote Intervention in Patients With SCAD N/A